Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
New inhalers would have near-zero Global Warming Potential propellant
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
Subscribe To Our Newsletter & Stay Updated
